Mahana Therapeutics Raises $61M in Series B Financing
- Mahana Therapeutics, CA-based developer of prescription digital therapeutics designed to empower patients with chronic health conditions, raised $61m in Series B financing
- The round was led by JAZZ Venture Partners and Gurnet Point Capital with participation from new and existing investors Main Street Advisors, KKCG and Lux Capital
- Sophie Kornowski of Gurnet Point and Meghan Reynolds of JAZZ have joined the Mahana Therapeutics Board of Directors
- The company will use the funds to launch the FDA-cleared prescription digital therapeutic Mahana™ IBS
- The company is a developer of prescription digital therapeutics that are designed to empower patients with chronic conditions
- The company’s first product, Mahana IBS, is a digital therapeutic that has demonstrated effectiveness in a 558-patient clinical trial in individuals with irritable bowel syndrome
